These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31311349)

  • 1. New developments in pharmacotherapy for Friedreich ataxia.
    Clay A; Hearle P; Schadt K; Lynch DR
    Expert Opin Pharmacother; 2019 Oct; 20(15):1855-1867. PubMed ID: 31311349
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological therapeutics in Friedreich ataxia: the present state.
    Strawser C; Schadt K; Hauser L; McCormick A; Wells M; Larkindale J; Lin H; Lynch DR
    Expert Rev Neurother; 2017 Sep; 17(9):895-907. PubMed ID: 28724340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies in Friedreich's Ataxia.
    Zesiewicz TA; Hancock J; Ghanekar SD; Kuo SH; Dohse CA; Vega J
    Expert Rev Neurother; 2020 Dec; 20(12):1215-1228. PubMed ID: 32909841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data.
    Gunther K; Lynch DR
    Expert Opin Pharmacother; 2024 Apr; 25(5):529-539. PubMed ID: 38622054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches for the treatment of Friedreich's ataxia.
    Strawser CJ; Schadt KA; Lynch DR
    Expert Rev Neurother; 2014 Aug; 14(8):949-57. PubMed ID: 25034024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Friedreich ataxia: an update on animal models, frataxin function and therapies.
    González-Cabo P; Llorens JV; Palau F; Moltó MD
    Adv Exp Med Biol; 2009; 652():247-61. PubMed ID: 20225031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for Friedreich ataxia.
    Tsou AY; Friedman LS; Wilson RB; Lynch DR
    CNS Drugs; 2009; 23(3):213-23. PubMed ID: 19320530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing phase II clinical trials in Friedreich ataxia.
    Rodden LN; Lynch DR
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):415-423. PubMed ID: 34693848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
    Profeta V; McIntyre K; Wells M; Park C; Lynch DR
    Expert Opin Investig Drugs; 2023 Jan; 32(1):5-16. PubMed ID: 36708320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frataxin-deficient neurons and mice models of Friedreich ataxia are improved by TAT-MTScs-FXN treatment.
    Britti E; Delaspre F; Feldman A; Osborne M; Greif H; Tamarit J; Ros J
    J Cell Mol Med; 2018 Feb; 22(2):834-848. PubMed ID: 28980774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.
    Yiu EM; Tai G; Peverill RE; Lee KJ; Croft KD; Mori TA; Scheiber-Mojdehkar B; Sturm B; Praschberger M; Vogel AP; Rance G; Stephenson SE; Sarsero JP; Stockley C; Lee CY; Churchyard A; Evans-Galea MV; Ryan MM; Lockhart PJ; Corben LA; Delatycki MB
    J Neurol; 2015 May; 262(5):1344-53. PubMed ID: 25845763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omaveloxolone: potential new agent for Friedreich ataxia.
    Lynch DR; Johnson J
    Neurodegener Dis Manag; 2021 Apr; 11(2):91-98. PubMed ID: 33430645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label pilot study of interferon gamma-1b in Friedreich ataxia.
    Seyer L; Greeley N; Foerster D; Strawser C; Gelbard S; Dong Y; Schadt K; Cotticelli MG; Brocht A; Farmer J; Wilson RB; Lynch DR
    Acta Neurol Scand; 2015 Jul; 132(1):7-15. PubMed ID: 25335475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
    Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecules affecting transcription in Friedreich ataxia.
    Gottesfeld JM
    Pharmacol Ther; 2007 Nov; 116(2):236-48. PubMed ID: 17826840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of diazoxide on Friedreich ataxia models.
    Santoro A; Anjomani Virmouni S; Paradies E; Villalobos Coa VL; Al-Mahdawi S; Khoo M; Porcelli V; Vozza A; Perrone M; Denora N; Taroni F; Merla G; Palmieri L; Pook MA; Marobbio CMT
    Hum Mol Genet; 2018 Mar; 27(6):992-1001. PubMed ID: 29325032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia.
    Evans-Galea MV; Lockhart PJ; Galea CA; Hannan AJ; Delatycki MB
    Discov Med; 2014 Jan; 17(91):25-35. PubMed ID: 24411698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell and gene therapy for Friedreich ataxia: progress to date.
    Evans-Galea MV; Pébay A; Dottori M; Corben LA; Ong SH; Lockhart PJ; Delatycki MB
    Hum Gene Ther; 2014 Aug; 25(8):684-93. PubMed ID: 24749505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
    Cooper JM; Schapira AH
    Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients.
    Alemany-Perna B; Tamarit J; Cabiscol E; Delaspre F; Miguela A; Huertas-Pons JM; Quiroga-Varela A; Merchan Ruiz M; López Domínguez D; Ramió I Torrentà L; Genís D; Ros J
    Mov Disord; 2024 Jul; 39(7):1099-1108. PubMed ID: 38696306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.